ArticleMolecules (Basel, Switzerland)2020
Evaluation of a
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Evaluation of [Molecules (Basel, Switzerland) · 2021Trial
- Structure-guided phage display discovery of antibodies for (S)Tn-glycans in protein context.Nature chemical biology · 2026Article
- Article
- [RSC chemical biology · 2024Article
- Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model.PloS one · 2024Article
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- Click chemistry: a transformative technology in nuclear medicine.Nature protocols · 2023Review
- Clearing and Masking Agents in Pretargeting Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2022Review
- Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers.Pharmaceutics · 2022Article
- Radiolabelling small and biomolecules for tracking and monitoring.RSC advances · 2022Review
- Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Pretargeted PET of Osteodestructive Lesions in Dogs.Molecular pharmaceutics · 2022Article
- Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [Bioconjugate chemistry · 2022Article
- Insights into Elution of Anion Exchange Cartridges: Opening the Path toward AliphaticACS pharmacology & translational science · 2021Article
- Direct Cu-mediated aromaticChemical science · 2021Article
- Lipophilicity and Click Reactivity Determine the Performance of Bioorthogonal Tetrazine Tools in PretargetedACS pharmacology & translational science · 2021Article
- Clickable Radiocomplexes With Trivalent Radiometals for Cancer Theranostics:Frontiers in medicine · 2021Article
- Carbon Nanomaterials for Sorption ofNanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
The bioorthogonal reaction between a tetrazine and strained transcyclooctene (TCO) has garnered success in pretargeted imaging. This reaction was first validated in nuclear imaging using an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.